Jump to comment:
- Page navigation anchor for RE: The Potential Toxicity of Topical Ocular SolutionsRE: The Potential Toxicity of Topical Ocular Solutions
Kisilevsky and DeAngelis illustrate the occurrence of ocular vasculopathy in association with the administration of a topical eye decongestant.1 The pathogenesis and clinical manifestations essentially parallel the complications of α-adrenergic agent use in other diseases such as rhinitis medicamentosa and dermatitis medicamentosa.2,3 It may very well be, however, that any such rebound vascular effects are also influenced by co-factors such as benzalkonium chloride (BAK) which may be present as preservatives in these pharmacological solutions.4 The general medical community is unlikely to consider that preservatives in almost any topical ocular product may cause direct toxicity or local allergic reactions in some patients. Either of the latter could be associated subsequently with an actual or presumed vasculopathy.
Show More
BAK is one of the most common and potentially toxic preservatives in topical eye solutions.5 Concentrations of this chemical vary from 0.005% to 0.02% in many targeted therapeutic ocular solutions (e.g., combined with active agents for glaucoma) or in putatively soothing or hydrating solutions more popularly referred to as ‘natural tears’.6 BAK can disrupt surface corneal epithelium, alter surface tear film formation, and lead to surface structure necrosis.6,7 Such toxicity is dose-dependent and time-accrued.6-8 In animal models, aganglionosis of esophagus or bowel can be achieved by brief local exposures to BAK with similar or slightly higher concentrat...Competing Interests: None declared.